Aβ40 oligomers identified as a potential biomarker for the diagnosis of alzheimer's disease

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Gao, Carol Man ^a   Yam, Alice Y ^a   Wang, Xuemei ^a   Magdangal, Erika ^a   Salisbury, Cleo ^a   Peretz, David ^a   Zuckermann, Ronald N ^d   Connolly, Michael D ^d   Hansson, Oskar ^c   Minthon, Lennart ^c   Zetterberg, Henrik ^b   Blennow, Kaj ^b   Fedynyshyn, Joseph P ^a   Allauzen, Sophie ^a  

^a Research and Development   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; EPITOPE; PEPTIDE; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN FOLDING; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BRAIN; CEREBROSPINAL FLUID; CHEMICAL MODEL; CHEMISTRY; CONFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PROTEIN CONFORMATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN CONFORMATION; SENSITIVITY AND SPECIFICITY;

EID: 78651269012     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015725     Document Type: Article

References (38)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
2. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678-699.
3. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
4. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443: 774-779.
5. Caroli A, Frisoni GB (2009) Quantitative evaluation of Alzheimer's disease. Expert Rev Med Devices 6: 569-588.
6. Urbanelli L, Magini A, Ciccarone V, Trivelli F, Polidoro M, et al. (2009) New perspectives for the diagnosis of Alzheimer's disease. Recent Pat CNS Drug Discov 4: 160-181.
7. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357.
8. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
9. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79: 595-605.
10. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28: 4231-4237.
11. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr., et al. (1995) Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270: 7013-7016.
12. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45-53.
13. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101: 1172-1184.
14. Citron M, Westaway D, Xia W, Carlson G, Diehl T, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72.
15. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, et al. (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447: 453-457.
16. Leliveld SR, Korth C (2007) The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. J Neurosci Res 85: 2285-2297.
17. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
18. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18.
19. Lau AL, Yam AY, Michelitsch MM, Wang X, Gao C, et al. (2007) Characterization of prion protein (PrP)-derived peptides that discriminate fulllength PrPSc from PrPC. Proc Natl Acad Sci U S A 104: 11551-11556.
20. Pitschke M, Prior R, Haupt M, Riesner D (1998) Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4: 832-834.
21. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, et al. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102: 2273-2276.
22. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, et al. (2010) Highmolecular- weight {beta}-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. Faseb J.
23. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95: 834-847.
24. American Psychiatric Association Work Group to Revise DSM-III (1987) Diagnostic and statistical manual of mental disorders: DSM-III-R. Washington, DC: American Psychiatric Association. xxix, 567.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
26. Nguyen JT, Porter M, Amoui M, Miller WT, Zuckermann RN, et al. (2000) Improving SH3 domain ligand selectivity using a non-natural scaffold. Chem Biol 7: 463-473.
27. Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, et al. (1992) Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A 89: 9367-9371.
28. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
29. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60: 1119-1122.
30. Weller RO, Nicoll JA (2003) Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 25: 611-616.
31. Haglund M, Kalaria R, Slade JY, Englund E (2006) Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. Acta Neuropathol 111: 430-435.
32. Jellinger KA (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases. Neurodegener Dis 7: 112-115.
33. Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229-230: 37-41.
34. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, et al. (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol.
35. Jarrett JT, Berger EP, Lansbury PT, Jr. (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697.
36. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, et al. (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid betaprotein (Abeta) assembly from Alzheimer disease brains. J Biol Chem 284: 32895-32905.
37. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, et al. (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 100: 6370-6375.
38. Takeda S, Sato N, Niisato K, Takeuchi D, Kurinami H, et al. (2009) Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Res 1280: 137-147.